Treatment of Acute Myeloid Leukemia in the Era of Genomics-Achievements and Persisting Challenges.

ABSTRACT: Acute myeloid leukemia (AML) represents a malignant disorder of the hematopoietic system that is mainly characterized by rapid proliferation, dysregulated apoptosis, and impaired differentiation of leukemic blasts. For several decades, the diagnostic approach in AML was largely based on histologic characteristics with little impact on the treatment decision-making process. This perspective has drastically changed within the past years due to the advent of novel molecular technologies, such as whole genome next-generation sequencing (NGS), and the resulting knowledge gain in AML biology and pathogenesis. After more than four decades of intensive chemotherapy as a "one-size-fits-all" concept, several targeted agents have recently been approved for the treatment of AML, either as single agent

SUBMITTER: Green SD 

PROVIDER: S-EPMC7267060 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature